Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash	$ 12,354,391		$ 12,354,391		$ 1,182,412
Allowance for doubtful accounts	74		74		$ 0
Revenues from sale of treatability services			30,317	$ 63,775
Revenues from sales			833,294	2,162,702
Research And Development Cost	$ 317,573	$ 118,253	$ 945,443	$ 726,602
Warrants [Member]
Antidilutive Excluded from Computation of Earnings Per Share, Amount			1,235,000		1,250,000
Options [Member]
Antidilutive Excluded from Computation of Earnings Per Share, Amount			10,628,000		12,752,000